At a glance
ClinicalIndex Comparison RecordN/ACompleted· 56 enrolled
Drug / intervention
Resolute Integrity Stentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Resolute Integrity US A Postapproval Study of the Medtronic Resolute™ Integrity Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2 mm
In Brief
A clinical study evaluating Resolute Integrity Stent for Coronary Artery Disease. Completed, enrolled 56 participants across 1 site.
Detailed Summary
Prospective, multi-center, non-randomized, single-arm, open-label study to assess the safety and efficacy of the Resolute Integrity Stent for the treatment of de novo lesions in native coronary arteries with a reference vessel diameter (RVD) of 2.25 mm to 4.2 mm in patients who receive extended length stents (34 mm or 38 mm) referred to as the Extended Length Study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJul 2013
First PostedAug 2013
Primary CompletionOct 2016
Study CompletionDec 2018
TodayJul 2026
First PostedAug 1, 2013
Enrollment StartJul 1, 2013
Primary CompletionOct 1, 2016
Study CompletionDec 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 12.9 years ago
Interventions
Resolute Integrity Stentdevice
Drug eluting stent (DES)